Magle Chemoswed (MAGLE) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue rose to 52.4 MSEK from 46.0 MSEK year-over-year, but EBITDA dropped to -20.6 MSEK from 5.3 MSEK, reflecting integration costs and supply chain delays.

• Operating profit (EBIT) for Q2 was -29.0 MSEK versus 1.3 MSEK last year; profit after tax was -27.8 MSEK compared to 0.2 MSEK.

• Strategic transformation continued with integration of Magle Biopolymers and Magle Biopharma, and acquisition of Saving Chlora.

• Senior secured bonds of SEK 350 million were issued to refinance debt and fund integration and expansion.

Financial highlights

• H1 2025 revenue reached 133.8 MSEK, up from 84.2 MSEK year-over-year.

• H1 2025 EBITDA was -1.8 MSEK, down from 12.4 MSEK; EBIT was -26.9 MSEK versus 5.5 MSEK.

• Earnings per share for Q2 was -1.35, down from 0.01 year-over-year; H1 EPS was -1.40 versus 0.29.

• Equity ratio stood at 51% at the end of Q2 2025.

• Cash flow from operating activities in Q2 was -17.1 MSEK; cash and cash equivalents at period end were 2.15 MSEK.

Outlook and guidance

• Management expects improved performance in H2 2025 as supply chain issues are resolved and integration synergies materialize.

• No loss of market share or major contracts; revenue recognition delayed due to supply disruptions, not demand.

• Focus remains on disciplined execution, innovation, and sustainable shareholder value.